[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Swiss Federal Institute of Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":227},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,76,105,130,151,179,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644773","generalizability-of-unsupervised-therapy-after-stroke-in-the-home-setting-with-a-hand-rehabilitation-device-rehandybot-100644773",false,"NCT07674238","Generalizability of Unsupervised Therapy After Stroke in the Home Setting With a Hand Rehabilitation Device (ReHandyBot)","Generalizability of Unsupervised Therapy After Stroke in the Home Setting With a Hand Rehabilitation Device (ReHandyBot): a Multicentric, Exploratory Study","RHB Home SNR","Inclusion Criteria:\n\n* Informed Consent signed by the subject;\n* female and male patients between 18 and 90 years old;\n* acute\u002Fsubacute stroke (recruitment within 12 weeks from stroke onset);\n* pre-stroke modified Rankin score ≤ 1;\n* National Institutes of Health Stroke Scale (NIHSS) ≥ 1 in at least one of the items regarding motor functions, sensory functions and ataxia;\n* possibility (e.g., enough space) to set up the ReHandyBot at home.\n\nExclusion Criteria:\n\n* modified Ashworth Scale \\> 2 for one or more of the following muscles: shoulder adductors, forearm pronator and supinator, flexors and extensors of elbow, wrist and fingers;\n* moderate to severe aphasia: Goodglass-Kaplan's scale \\\u003C 3;\n* moderate to severe cognitive deficits: levels of cognitive functioning-revised (LCF-R) \\\u003C 9;\n* functional impairment of the upper limb due to other pathologies;\n* severe pain in the affected arm: visual analogue scale for pain (VASp) ≥ 5;\n* other pathologies which may interfere with the study;\n* after discharge the patient will go to an assisted living facility (e.g., care home).","ALL","18 Years","90 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The ReHandyBot (RHB) is a robot for hand rehabilitation after stroke. The aims of this study are to investigate (i) the generalizability of unsupervised therapy with the ReHandyBot within patients' home after discharge from a clinic, (ii) compliance, as measured by the amount of unsupervised robot-assisted therapy dose (e.g., therapy time) performed by the subjects after discharge, (iii) the usability of ReHandyBot and user experience during robot-assisted therapy, and (iv) the effect of the increase in therapy dose achieved with our device compared to standard care. The study consists of two primary phases. The first is a familiarization phase conducted at the clinic, where therapists teach participants how to perform the exercises using the robot. Then, if capable of training with the robot safely, after discharge from the clinic, participants can bring the robot home and autonomously train with it. The hypothesis is that unsupervised therapy might be a possible way to increase therapy dose for stroke patients, with the potential to further improve recovery of hand function, with minimal additional burden for therapists and for the healthcare system.",[28],"Stroke",[28,30,31,32,33],"Hand impairment","Robot-assisted therapy","Unsupervised therapy","Neurorehabilitation","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2028-08-30",{"name":44,"class":45},"Swiss Federal Institute of Technology","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100519184","arrhythmogenic-activity-during-exercise-in-arvc-patients-100519184","NCT06040242","Arrhythmogenic Activity During Exercise in ARVC Patients","Characterization of Arrhythmogenic Activity During and After Physical Exercise in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)","Inclusion Criteria:\n\n* Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria\n* Pathogenic \u002F likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic \u002F likely pathogenic variant found)\n* Control group: diagnosed ischemic heart disease with ejection fraction above 35%\n* Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient\n* No history of exercise-induced syncope in the 6 months prior to study participation\n* No history of sudden cardiac arrest in the 6 months prior to study participation\n* In patients who suffered from sudden cardiac arrest\u002Farrhythmic syncope, only those having an implantable cardioverter-defibrillator (ICD) and being under beta-blockers\u002Fantiarrhythmic drugs are eligible for study inclusion\n* Informed Consent as documented by signature (Appendix Informed Consent Form)\n* Age: \\> 14 years\n* Body-Mass-Index (BMI): 18.5 - 39.9 kg･m-2\n* Willing to adhere to the following study rules:\n\n  * No intense exercise 48h prior to testing\n  * No exercise 24h prior to testing\n  * Sleep at least 7h the two nights before testing On test day\n  * No caffeinated food or drink before testing on test day\n  * No alcohol before testing on test day\n  * Fully compliant with normal medication regimen including beta-blockers and antiarrhythmic medication\n\nExclusion Criteria:\n\n* No genetic test history for ARVC variants\n* Heart failure with severely reduced left ventricular ejection fraction (LVEF \\\u003C35%)\n* For women: Pregnancy, breastfeeding, or intention to become pregnant during the study.\n* Known or suspected non-compliance, drug, or alcohol abuse\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant\n* Previous enrolment into the current study",true,"14 Years",{"count":57,"type":22},120,[25],"Current guidelines advocate that ARVC patients, typically young and active individuals with a significant history of competitive endurance sports, cease endurance training in favour of activities with low cardiac burden such as bowling and golf. Empirically, it is often suggested that heart rate during exercise should not exceed 100-120 bpm in these patients, but these guidelines are arbitrary and not scientifically based. In practice, it is estimated that up to 50% of patients do not comply with these recommendations .\n\nAdequate quantification of the arrhythmogenic burden, defined as premature ventricular beats in proportion to all heart beats in each period of time, and cardiac load (defined as stroke volume for volume load and systolic blood pressure for pressure load) experienced by ARVC patients when performing different types of physical exercise would be a first step towards designing a safe and effective intervention so that these patients can profit from an active life style.\n\nThis study therefore aims to quantify and describe the arrhythmogenic burden and cardiac load experienced by patients with ARVC while performing different physical exercise over a range of intensities - all strictly within the range currently recommended by different cardiological societies.",[61],"Arrhythmogenic Right Ventricular Cardiomyopathy",[63,64,65],"exercise","cycling","physical activity","RECRUITING","2026-03-19",{"date":69,"type":38},"2026-03-24",{"date":71,"type":38},"2023-08-01",{"date":73,"type":22},"2027-12-31",{"name":44,"class":45},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100606990","feasibility-of-unsupervised-therapy-after-neurological-or-orthopaedical-injury-in-the-home-setting-with-a-hand-rehabilitation-device-rehandybot-and-an-assistive-smartphone-application-rehabcoach-100606990","NCT07182734","Feasibility of Unsupervised Therapy After Neurological or Orthopaedical Injury in the Home Setting With a Hand Rehabilitation Device (ReHandyBot) and an Assistive Smartphone Application (RehabCoach)","Feasibility of Unsupervised Therapy After Neurological or Orthopaedical Injury in the Home Setting With a Hand Rehabilitation Device (ReHandyBot) and an Assistive Smartphone Application (RehabCoach): an Exploratory Study","Eligibility criteria for neurological patients\n\nInclusion criteria:\n\n* Informed Consent signed by the subject.\n* Female and male patients between 18 and 90 years old.\n* Stroke or traumatic brain injury (recruitment within 6 months from event onset).\n* Presence of a motor and\u002For sensory impairment of the upper limb as assessed by the responsible therapist.\n* Possibility (e.g., enough space) to set up the ReHandyBot at home.\n\nExclusion criteria:\n\n* Modified Ashworth Scale \\> 2 for one or more of the following muscles: shoulder adductors, forearm pronator and supinator, flexors and extensors of elbow, wrist and fingers.\n* Moderate to severe aphasia: Goodglass-Kaplan's scale \\\u003C 3.\n* Moderate to severe cognitive deficits: levels of cognitive functioning-revised (LCF-R) \\\u003C 9.\n* Functional impairment of the upper limb due to other pathologies.\n* Severe pain in the affected arm: visual analogue scale for pain (VASp) ≥ 5.\n* Other pathologies which may interfere with the study.\n* After discharge, the patient will go to an assisted living facility (e.g., care home).\n\nEligibility criteria for orthopedic patients\n\nInclusion criteria:\n\n* Informed Consent signed by the subject.\n* Female and male patients between 18 and 90 years old.\n* Clinic stay due to an orthopedic-related condition (e.g., surgery, trauma, burns).\n* Presence of a motor and\u002For sensory impairment of the upper limb as assessed by the responsible therapist.\n* Possibility (e.g., enough space) to set up the ReHandyBot at home.\n\nExclusion criteria:\n\n* Moderate to severe aphasia: Goodglass-Kaplan's scale \\\u003C 3.\n* Moderate to severe cognitive deficits: levels of cognitive functioning-revised (LCF-R) \\\u003C 9.\n* Functional impairment of the upper limb due to other pathologies.\n* Severe pain in the affected arm: visual analogue scale for pain (VASp) ≥ 5.\n* Other pathologies which may interfere with the study.\n* After discharge, the patient will go to an assisted living facility (e.g., care home).",{"count":84,"type":22},30,[25],"The goal of this clinical trial is to evaluate whether using the ReHandyBot hand rehabilitation device together with the RehabCoach smartphone app can support safe, independent, and effective home therapy in patients with stroke, traumatic brain injury, or orthopedic problems.\n\nThe main questions it aims to answer are:\n\n* Can patients safely and independently use ReHandyBot and RehabCoach after leaving the clinic?\n* Will patients follow the recommended daily therapy schedule when using these tools at home?\n* How do patients experience the usability and acceptability of ReHandyBot and RehabCoach in everyday life?\n* Can this type of home-based therapy be extended to populations beyond stroke, such as traumatic brain injury and orthopedic patients?\n\nParticipants will:\n\n* Complete a screening and baseline assessment with a therapist.\n* Use ReHandyBot in a supervised phase at the clinic (3 sessions of 30 minutes).\n* Continue with a minimally supervised phase at the clinic (3-7 sessions of 30 minutes, with daily app use).\n* If ready, enter the unsupervised phase, taking ReHandyBot home for daily 30-minute training sessions, supported by RehabCoach.\n* Return for a final assessment including clinical and robotic evaluations and usability feedback.",[88],"Rehabilitation After Neurological or Orthopaedic Injuries",[90,91,92,93,94,95,96],"rehabilitation","stroke","traumatic brain injury","robotic devices","unsupervised therapy","hand training","upper limb therapy","2025-09-12",{"date":99,"type":38},"2025-09-19",{"date":101,"type":22},"2025-09-15",{"date":103,"type":22},"2028-08-01",{"name":44,"class":45},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":75},"100581501","assessing-the-immediate-increase-in-serum-ferritin-after-oral-iron-doses-an-experimental-study-in-iron-deficient-women-100581501","NCT06851130","Assessing the Immediate Increase in Serum Ferritin After Oral Iron Doses: an Experimental Study in Iron-deficient Women","INFER 2","Inclusion Criteria:\n\n* Low iron stores (SF levels \\\u003C 30 µg\u002FL),\n* no anemia (Hb \\> 120 g\u002FL)\n* no inflammation (CRP \\\u003C 5 mg\u002FL)\n* 18 to 45 years old.\n* Body weight \\\u003C70 kg\n* Normal body Mass Index (18.5-26.5 kg\u002Fm2)\n\nExclusion Criteria:\n\n* Any chronic or acute disease\n* Consumption of mineral and vitamin supplements since screening and over the study period\n* Blood transfusion, blood donation or significant blood loss over the past 4 months,\n* Pregnant or breastfeeding,\n* Continuous\u002Flong-term use of medication during the whole studies (except for contraceptives)\n* Therapeutic iron infusion over the past 6 months,\n* Known hypersensitivity or allergy to iron supplements,\n* Intention to become pregnant over the course of the study","FEMALE","45 Years",{"count":57,"type":22},[25],"Serum ferritin is a key indicator of body iron stores and is widely used in monitoring iron status. However, oral iron doses can acutely elevate SF levels, potentially biasing assessments of iron stores during supplementation. This study aims to investigate the extent and duration of the acute iron-induced effect on serum ferritin following the administration of a daily iron dose for two months.",[118],"Iron Deficiency Without Anemia",[120,121],"serum ferritin","oral iron supplementation","2025-05-19",{"date":124,"type":38},"2025-05-20",{"date":126,"type":38},"2025-02-25",{"date":128,"type":22},"2025-12-31",{"name":44,"class":45},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":112,"minAge":18,"maxAge":113,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":75},"100363125","hepcidin-and-glucose-metabolism-100363125","NCT04008147","Hepcidin and Glucose Metabolism","The Effect of Oral Iron Supplements on Hepcidin, Insulin and Glucose Metabolism in Pregnancy","Inclusion Criteria:\n\n* week of pregnancy 24-28\n* pre-pregnancy BMI \\\u003C27.5kg\u002Fm2\n* singleton pregnancy\n* Hb \\> 8.0 g\u002Fdl\n\nWilling to either:\n\n* not take any iron supplements for 14 days (however, participants will receive a similar amount of total iron during the 4 study days that they would normally receive over 14 days) OR\n* to take the multivitamin \"Burgerstein Schwangerschaft and Stillzeit\" supplements over the 14 days (contains 30 mg iron)\n\nExclusion Criteria:\n\n* iron infusion within the past 6 months\n* severely anemic Hb\\\u003C8.0g\u002Fdl\n* acute or chronic disease\n* long-term medication\n* medical problems known to affect iron homeostasis\n* smoking",{"count":84,"type":22},[25],"Gestational diabetes mellitus (GDM), defined as hyperglycemia with blood glucose values above normal but below those diagnostic of DM, and iron deficiency (ID) with or without anemia (IDA) are common during pregnancy. Both disease patterns are associated with an increased risk of complications during pregnancy and at delivery and may have a variety of negative effects on different aspects of child development. Thus, GDM and ID\u002FIDA during pregnancy should be prevented.\n\nWhether iron supplementation with high oral doses acutely increases hepcidin during pregnancy, and whether this acute iron-induced increase in hepcidin decreases insulin sensitivity, is uncertain.",[141,142,143,144],"Iron Deficiency Anemia of Pregnancy","Iron Metabolism Disorders","Glucose Intolerance","Gestational Diabetes",{"date":146,"type":38},"2025-05-22",{"date":148,"type":38},"2019-07-03",{"date":128,"type":22},{"name":44,"class":45},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100571863","feasibility-and-cost-of-robot-assisted-upper-limb-rehabilitation-with-different-levels-of-supervision-100571863","NCT06725784","Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation with Different Levels of Supervision","Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation with Different Levels of Supervision: an Interventional Study","RHB Clinic","Inclusion Criteria:\n\n* Informed Consent signed by the subject.\n* Female and male patients between 18 and 90 years old\n* Presence of an upper limb deficit derived from any disease or event that, according to the responsible clinicians, could be improved by therapy with ReHandyBot.\n\nExclusion Criteria:\n\n* Pathologies that may interfere with the training with ReHandyBot.",{"count":160,"type":22},100,[25],"Upper limb impairments are often a result of neurological or traumatic injuries (e.g., stroke, traumatic brain injuries). These impairments may decrease independence in performing activities of daily living, severely affecting patients' quality of life. Growing evidence shows that increasing upper limb therapy dose for patients could improve functional outcomes and prevent their long-term deterioration. However, due to limited resources (e.g., the number of therapists) and high rehabilitation-related costs, providing a higher therapy dose to patients is challenging, both in the clinic and after discharge, and finding new models of care is therefore critical.\n\nMinimally supervised or unsupervised robot-assisted therapy (i.e., patients training with rehabilitation devices with minimal to no supervision of an external person) holds the promise of allowing an increase in therapy dose with little impact on the additional resources needed. Because of their ability to provide active support and measure a wide set of parameters, actuated (active) rehabilitation robots seem to be the best solution for this therapy setting. However, such devices are often complex to use and have never been extensively tested minimally or unsupervised. Consequently, the data available on their feasibility and cost-effectiveness is limited.\n\nAt the Rehabilitation Engineering Laboratory (RELab, ETH Zurich), we developed ReHandyBot, an actuated device for unsupervised upper limb therapy. The device has already been tested with stroke patients in an unsupervised setting, with positive results regarding usability and increase in therapy dose. The main goal of this project is, therefore, to investigate the feasibility and cost of our robot-assisted continuum of care model (i.e., from inpatient to ambulatory). Specifically, we aim to evaluate the feasibility of integrating ReHandyBot into the clinical routine and perform a preliminary cost-benefit analysis of supervised, minimally supervised, and unsupervised robot-assisted therapy. Furthermore, we will also gather data on the overall dose of robot-assisted therapy and the intensity of use of the device in a clinical and ambulatory setting.",[164],"Upper Limb Sensorimotor Deficits",[94,166,91,167,168,169],"robot-assisted rehabilitation","neurorehabilitation","orthopaedic rehabilitation","upper limb rehabilitation","2025-03-03",{"date":172,"type":38},"2025-03-06",{"date":174,"type":22},"2025-03-04",{"date":176,"type":22},"2030-12-30",{"name":44,"class":45},2,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":188,"conditions":189,"keywords":192,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":75},"100502270","investigating-neural-biomarkers-for-gait-in-parkinsons-patients-100502270","NCT05820074","Investigating Neural Biomarkers for Gait in Parkinson's Patients","Inclusion Criteria:\n\nAll participants\n\n* must have given informed consent as documented by signature\n* agree to comply with the study procedures\n\nHealthy control group\n\n* no neurological, orthopedic, or rheumatologic disease history\n* no identified sensory impairment.\n* no epilepsy and self-diagnosed acute or chronic psychiatric disorders\n\nParkinson's Patients\n\n* non-tremor dominant idiopathic PD patients\n* presence of postural instability (UPDRS \\>1 for postural instability \\[17\\]), gait disturbance, and absence of other causes of reduced balance\n* Implanted with Percept™ PC neurostimulator\n* Able to be in the stimulation OFF\n\nExclusion Criteria:\n\n* Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) \\\u003C 20\n* History of physical or neurological condition that interferes with study procedures\n* Social and\u002For personal circumstances interfering with the ability to come to the session",{"count":186,"type":22},60,"OBSERVATIONAL","This observational study's main goal is to learn more about the neural mechanisms during movement in Parkinson's disease. Furthermore, it aims to inspire personalised treatment options.\n\nParticipants will undergo a protocol that involves walking and gait-related motor tasks, such as seated stepping. During the protocol, brain activity will be recorded.",[190,191],"Parkinson Disease","Gait Disorders, Neurologic",[193,194,195,196,197],"Parkinson's disease","gait parameters","neural activity","Percept PC","deep brain stimulation","2024-11-28",{"date":200,"type":38},"2024-12-03",{"date":202,"type":38},"2023-04-13",{"date":204,"type":22},"2025-03",{"name":44,"class":45},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":75},"100520481","unsupervised-therapy-after-stroke-in-the-home-setting-with-a-hand-rehabilitation-device-rehandybot-100520481","NCT06057129","Unsupervised Therapy After Stroke in the Home Setting with a Hand Rehabilitation Device (ReHandyBot)","Feasibility of Unsupervised Therapy After Stroke in the Home Setting with a Hand Rehabilitation Device (ReHandyBot): an Exploratory Study","Inclusion Criteria:\n\n* Informed Consent signed by the subject;\n* female and male patients between 18 and 90 years old;\n* acute\u002Fsubacute stroke (recruitment within 12 weeks from stroke onset);\n* pre-stroke modified Rankin score ≤ 1;\n* National Institutes of Health Stroke Scale (NIHSS) ≥ 1 in at least one of the items regarding motor functions, sensory functions and ataxia;\n* possibility (e.g., enough space) to set up the ReHandyBot at home.\n\nExclusion Criteria:\n\n* modified Ashworth Scale \\> 2 for one or more of the following muscles: shoulder adductors, forearm pronator and supinator, flexors and extensors of elbow, wrist and fingers;\n* moderate to severe aphasia: Goodglass-Kaplan's scale \\\u003C 3;\n* moderate to severe cognitive deficits: levels of cognitive functioning-revised (LCF-R) \\\u003C 9;\n* functional impairment of the upper limb due to other pathologies;\n* severe pain in the affected arm: visual analogue scale for pain (VASp) ≥ 5;\n* other pathologies which may interfere with the study;\n* pacemakers and other active implants;\n* after discharge the patient will go to an assisted living facility (e.g., care home).",{"count":214,"type":22},15,[25],"The ReHandyBot is a robot for hand rehabilitation after stroke. The aims of this study are (1) to investigate the feasibility of unsupervised therapy with the ReHandyBot with stroke inpatients, first in a rehabilitation clinic and then at participants' home, (2) to evaluate the usability of the ReHandyBot (user interface, implemented exercises, and gaming environment, which were adapted for independent usage), and (3) to quantify the dose of additional robotic therapy that patients perform without supervision.\n\nThe study consists of two primary phases. The first is a familiarization phase performed at the clinic, where therapists teach to the participants how to perform the exercises with the robot. Then, if capable of training with the robot safely, after discharge from the clinic participants can bring the robot home and autonomously train with it. The hypothesis is that unsupervised therapy might be a possible way to increase therapy dose for stroke patients, with the potential to further improve recovery of hand function, with minimal additional burden for therapists and for the healthcare system.",[28],[28,30,31,32,33],"2024-10-30",{"date":221,"type":38},"2024-11-01",{"date":223,"type":38},"2023-11-13",{"date":225,"type":22},"2026-04",{"name":44,"class":45},""]